Veritas Aortic Solutions Secures $12M to Develop Non-Surgical Aortic Treatments

Veritas Aortic Solutions Secures Major Funding for Non-Surgical Aortic Treatments

Veritas Aortic Solutions, a pioneering company in the field of medical devices, recently announced that it has successfully closed a seed financing round totaling $12 million. This funding will be instrumental in propelling the development of innovative, non-surgical treatments specifically targeting aortic root and ascending aortic diseases. The funding round was spearheaded by a group of strategically influential angel investors from the MedTech industry, boasting excellent participation from the Cedars-Sinai Intellectual Property Company, alongside support from prior investors linked to inQB8 Medical Technologies.

The capital raised will primarily focus on advancing the Veritas Transcatheter Valved Aortic Root Conduit (TVARC), a novel system slated for first-in-human clinical trials. This innovative technology aims to provide a comprehensive interventional solution for high-risk areas associated with root and ascending aortic diseases, including conditions such as dissections, aneurysms, and other related pathologies. The goal is to significantly reduce the risks that current surgical treatments pose to patients.

Arshad Quadri, MD, who co-founded Veritas, elaborated on the urgency and necessity of non-invasive treatment options in this challenging medical arena. With mortality and morbidity rates for acute ascending aorta conditions soaring as high as 65%, the need for safer alternatives to open-heart surgeries is critical. Quadri, who brings extensive experience from his background as a cardiac surgeon, emphasized that existing surgical procedures for these critical conditions remain complex and invasive.

"Being a cardiac surgeon, I have witnessed firsthand the complexity and challenges involved in treating patients with ascending aortic pathologies. They are highly invasive, and traditional surgical methods often involve significant risks," said Quadri. "The Veritas TVARC device aims to offer a faster and safer alternative, and we are now one step closer to achieving this dream."

The innovative Veritas TVARC system is designed as a single permanent implant, integrating a bioprosthetic aortic valve, an ascending aortic graft, and proprietary Chameleon Eye™ coronary perfusion ports. Together, these components work to seal off the damaged segments of the aorta while restoring normal blood flow to critical areas such as coronary arteries and distant parts of the body. This system is intended to be deployed through a specialized transfemoral delivery catheter, thereby potentially eliminating the need for invasive open-heart surgical interventions.

Nirdesh Gupta, PhD, Managing Partner at Cedars-Sinai Intellectual Property Company, expressed optimism regarding the implications of the new technology: "The Veritas TVARC system embodies a patient-centric innovation that we are proud to support. We recognize the tremendous risk associated with aortic root diseases, and we believe that this groundbreaking endovascular approach can substantially enhance treatment outcomes for patients suffering from life-threatening cardiovascular issues."

Furthermore, J. Brent Ratz, Co-Founder and CEO of Veritas Aortic Solutions, underscored the collaborative efforts that enabled the advance of the Veritas program within inQB8 Medical Technologies. He expressed gratitude for the backing of seasoned investors and esteemed medical professionals who will expedite the technological advancements towards clinical applications.

"Throughout our years of partnership, Dr. Quadri and I have dedicated ourselves to innovating solutions in the cardiovascular domain," stated Ratz. "Given the intricacies of root and ascending aortic diseases, and recognizing the profound need for effective interventional responses, Veritas is on track to make significant contributions with potential positive impacts on patient care."

As a newly minted independent entity, Veritas Aortic Solutions aims to reshape the treatment landscape for patients suffering from aortic diseases. By providing solutions that are both effective and less invasive than traditional surgical methods, Veritas hopes to change the narrative around cardiovascular health and improve patient outcomes significantly. For more information about their groundbreaking work, visit their official website: www.veritasaortic.com.

About Veritas Aortic Solutions

Founded as a spinout from inQB8 Medical Technologies, Veritas Aortic Solutions is dedicated to improving treatment methodologies for patients with aortic disease. It focuses on developing advanced technologies that address the needs of patients requiring intervention for urgent cardiovascular issues.

About inQB8 Medical Technologies

inQB8 Medical Technologies operates as a medical device incubator, backing innovative interventional solutions for prominent cardiovascular challenges, with a track record of successful product transitions into impactful healthcare tools.

About Cedars-Sinai Intellectual Property Company

Cedars-Sinai Intellectual Property Company invests in healthcare and life sciences startups, fostering advancements in medical technology, drugs, and regulated digital health solutions aimed at improving patient outcomes.